<DOC>
	<DOCNO>NCT02106260</DOCNO>
	<brief_summary>This phase I/IIa study open-label , First-in-Human ( FIH ) , single center design assess safety , pharmacokinetics ( PK ) pharmacodynamics ( PD ) multiple dose topically apply CLS003 healthy subject cutaneous wart .</brief_summary>
	<brief_title>First-in-Human Study CLS003 ICVT Subjects With Cutaneous Warts</brief_title>
	<detailed_description />
	<mesh_term>Warts</mesh_term>
	<criteria>Healthy subject ( male , nonpregnant female ) , 18 65 year age , inclusive . Body mass index ( BMI ) 18 30kg/m2 , inclusive Fitzpatrick skin type IIIIIIIV At least 4 cutaneous wart hand , separate least 1cm skin For woman , positive pregnancy test and/or nursing screen A positive test drug abuse screen History alcohol illicit drug abuse Positive test result Hepatitis B , Hepatitis C HIV Have use salicylic acid overthecounter wartremoving product treatment area within 30 day prior enrollment Have receive cryotherapy treatment area within 60 day prior enrollment Have require systemic intake immunosuppressive immunomodulatory medication ( include oral parenteral corticosteroid ) 30 day prior enrollment course study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>safety</keyword>
	<keyword>pharmacokinetics ( PK )</keyword>
	<keyword>pharmacodynamics ( PD )</keyword>
	<keyword>CLS003</keyword>
</DOC>